Announced Thu, 9 Jul · 10:57 IST
US FDA inspection successfully closed at Sellersville facility
Regulatory & Legal View source PDF
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+5.1%1-day move
₹168.00
prior close
₹173.18
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.0+0.8+0.8+0.3+5.1+3.5+2.3+2.1+4.5+6.8————
Up moveDown movePending
AI summary
Piramal Pharma's manufacturing facility in Sellersville, USA has received an Establishment Inspection Report (EIR) from the US FDA, successfully closing the inspection that had begun earlier (per the company's May 10, 2026 update). A successful closure with an EIR indicates the facility meets US regulatory standards and can continue normal operations and US shipments without enforcement action.
Likely market impact
Positive for shareholders — a clean FDA inspection closure removes regulatory uncertainty and supports uninterrupted US market supplies from this facility.